Alpha Anthony
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 2%
- Long-Term Effects of COVID-19
- Intracerebral and Subarachnoid Hemorrhage Research
Papers in
-
- SARS-CoV-2 and COVID-19 Research 5
- COVID-19 Clinical Research Studies 4
-
- Intracerebral and Subarachnoid Hemorrhage Research 3
- Journals
- The Lancet (9 papers)JAMA (5 papers)The Lancet Neurology (1 paper)The Lancet Diabetes & Endocrinology (1 paper)EClinicalMedicine (1 paper)
- Partner nations
- United KingdomAustraliaVietnam
In The Last Decade
Alpha Anthony
22 papers receiving 2.7k citations
Alpha Anthony's Hit Papers
Peers
Comparison fields: 5 of 110
- Infectious Diseases 1.2k
- Neurology 674
- Internal Medicine 116
- Applied Microbiology and Biotechnology 51
- Rehabilitation 132
Countries citing papers authored by Alpha Anthony
This map shows the geographic impact of Alpha Anthony's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alpha Anthony with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alpha Anthony more than expected).
Fields of papers citing papers by Alpha Anthony
This network shows the impact of papers produced by Alpha Anthony. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alpha Anthony. The network helps show where Alpha Anthony may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | 2018 | 214 | |
| 6 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 7 | 2021 | 163 | |
| 8 | 2019 | 145 | |
| 9 | 2017 | 129 | |
| 10 | 2022 | 104 | |
| 11 | 2022 | 99 | |
| 12 | 2023 | 83 | |
| 13 | 2019 | 71 | |
| 14 | 2022 | 64 | |
| 15 | 2023 | 45 | |
| 16 | 2023 | 34 | |
| 17 | 2021 | 32 | |
| 18 | 2022 | 29 | |
| 19 | 2023 | 24 | |
| 20 | 2024 | 23 |
About Alpha Anthony
Alpha Anthony is a scholar working on Infectious Diseases, Neurology, Rehabilitation, Nutrition and Dietetics and Cardiology and Cardiovascular Medicine, having authored 23 papers that have together received 2.8k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (4 papers), Intracerebral and Subarachnoid Hemorrhage Research (3 papers), Stroke Rehabilitation and Recovery (1 paper), Inflammatory Bowel Disease (1 paper), Atrial Fibrillation Management and Outcomes (1 paper), Kawasaki Disease and Coronary Complications (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (1.2k citations), Neurology (674 citations), Internal Medicine (116 citations), Applied Microbiology and Biotechnology (51 citations) and Rehabilitation (132 citations). Alpha Anthony has collaborated with scholars based in United Kingdom, Australia and Vietnam. Their work appears in journals such as The Lancet, JAMA, The Lancet Neurology, The Lancet Diabetes & Endocrinology and EClinicalMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.